PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.34%
Cash & equivalents declining -42.34% while AVXL's grows 602.24%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-42.34%
Below half of AVXL's 602.24%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.91%
Other current assets growth < half of AVXL's -100.00%. David Dodd sees a leaner approach to short-term items.
-41.98%
Below half of AVXL's 534.40%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-100.00%
1.25-1.5x AVXL's -80.73%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-100.00%
1.25-1.5x AVXL's -80.73%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
Below half of AVXL's 507.47%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-48.73%
Less than half of AVXL's 5.71%. David Dodd sees a more disciplined AP approach or lower volume.
-46.67%
Less than half of AVXL's -100.00%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.33%
Less than half of AVXL's 31.66%. David Dodd sees fewer expansions in other current obligations.
-39.56%
Less than half of AVXL's 18.01%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.56%
Less than half of AVXL's 18.01%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.24%
Similar yoy to AVXL's -1.21%. Walter Schloss sees parallel earnings retention vs. competitor.
99.72%
Less than half of AVXL's -9.20%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Above 1.5x AVXL's -14.25%. Michael Burry suspects a significant bump in 'other' equity items vs. competitor.
-51.92%
≥ 1.5x AVXL's -15.77%. David Dodd sees stronger capital base growth than competitor.
-42.01%
Below half AVXL's 507.47%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-46.67%
Less than half of AVXL's 100.33%. David Dodd sees less overall debt expansion vs. competitor.
42.23%
50-75% of AVXL's 80.51%. Bruce Berkowitz notes comparatively lower net debt expansion.